Novel bioactivity of ellagic acid in inhibiting human platelet activation

Yi Chang, Wei Fan Chen, Kuan Hung Lin, Cheng Ying Hsieh, Duen Suey Chou, Li Jyun Lin, Joen Rong Sheu, Chao Chien Chang

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Pomegranates are widely consumed either as fresh fruit or in beverage form as juice and wine. Ellagic acid possesses potent antioxidative properties; it is known to be an effective phytotherapeutic agent with antimutagenic and anticarcinogenic qualities. Ellagic acid (20 to 80 M) exhibited a potent activity in inhibiting platelet aggregation stimulated by collagen; however, it did not inhibit platelet aggregation stimulated by thrombin, arachidonic acid, or U46619. Treatment with ellagic acid (50 and 80 M) significantly inhibited platelet activation stimulated by collagen; this alteration was accompanied by the inhibition of relative [ Ca 2+ ] i mobilization, and the phosphorylation of phospholipase C (PLC)γ2, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt, as well as hydroxyl radical (OH) formation. In addition, ellagic acid also inhibited p38 MAPK and Akt phosphorylation stimulated by hydrogen peroxide. By contrast, ellagic acid did not significantly affect PKC activation and platelet aggregation stimulated by PDBu. This study is the first to show that, in addition to being considered a possible agent for preventing tumor growth, ellagic acid possesses potent antiplatelet properties. It appears to initially inhibit the PLC γ 2-PKC cascade and/or hydroxyl radical formation, followed by decreased phosphorylation of MAPKs and Akt, ultimately inhibiting platelet aggregation.

Original languageEnglish
Article number595128
JournalEvidence-based Complementary and Alternative Medicine
Volume2013
DOIs
Publication statusPublished - 2013

Fingerprint

Ellagic Acid
Platelet Activation
Platelet Aggregation
Protein Kinase C
Phosphorylation
Type C Phospholipases
Mitogen-Activated Protein Kinases
Hydroxyl Radical
Collagen
Antimutagenic Agents
Anticarcinogenic Agents
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
Beverages
p38 Mitogen-Activated Protein Kinases
Wine
Arachidonic Acid
Thrombin
Hydrogen Peroxide
Fruit
Growth

ASJC Scopus subject areas

  • Complementary and alternative medicine

Cite this

Novel bioactivity of ellagic acid in inhibiting human platelet activation. / Chang, Yi; Chen, Wei Fan; Lin, Kuan Hung; Hsieh, Cheng Ying; Chou, Duen Suey; Lin, Li Jyun; Sheu, Joen Rong; Chang, Chao Chien.

In: Evidence-based Complementary and Alternative Medicine, Vol. 2013, 595128, 2013.

Research output: Contribution to journalArticle

@article{b741dbfbc1d54855bf426787e8910d68,
title = "Novel bioactivity of ellagic acid in inhibiting human platelet activation",
abstract = "Pomegranates are widely consumed either as fresh fruit or in beverage form as juice and wine. Ellagic acid possesses potent antioxidative properties; it is known to be an effective phytotherapeutic agent with antimutagenic and anticarcinogenic qualities. Ellagic acid (20 to 80 M) exhibited a potent activity in inhibiting platelet aggregation stimulated by collagen; however, it did not inhibit platelet aggregation stimulated by thrombin, arachidonic acid, or U46619. Treatment with ellagic acid (50 and 80 M) significantly inhibited platelet activation stimulated by collagen; this alteration was accompanied by the inhibition of relative [ Ca 2+ ] i mobilization, and the phosphorylation of phospholipase C (PLC)γ2, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt, as well as hydroxyl radical (OH) formation. In addition, ellagic acid also inhibited p38 MAPK and Akt phosphorylation stimulated by hydrogen peroxide. By contrast, ellagic acid did not significantly affect PKC activation and platelet aggregation stimulated by PDBu. This study is the first to show that, in addition to being considered a possible agent for preventing tumor growth, ellagic acid possesses potent antiplatelet properties. It appears to initially inhibit the PLC γ 2-PKC cascade and/or hydroxyl radical formation, followed by decreased phosphorylation of MAPKs and Akt, ultimately inhibiting platelet aggregation.",
author = "Yi Chang and Chen, {Wei Fan} and Lin, {Kuan Hung} and Hsieh, {Cheng Ying} and Chou, {Duen Suey} and Lin, {Li Jyun} and Sheu, {Joen Rong} and Chang, {Chao Chien}",
year = "2013",
doi = "10.1155/2013/595128",
language = "English",
volume = "2013",
journal = "Evidence-based Complementary and Alternative Medicine",
issn = "1741-427X",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Novel bioactivity of ellagic acid in inhibiting human platelet activation

AU - Chang, Yi

AU - Chen, Wei Fan

AU - Lin, Kuan Hung

AU - Hsieh, Cheng Ying

AU - Chou, Duen Suey

AU - Lin, Li Jyun

AU - Sheu, Joen Rong

AU - Chang, Chao Chien

PY - 2013

Y1 - 2013

N2 - Pomegranates are widely consumed either as fresh fruit or in beverage form as juice and wine. Ellagic acid possesses potent antioxidative properties; it is known to be an effective phytotherapeutic agent with antimutagenic and anticarcinogenic qualities. Ellagic acid (20 to 80 M) exhibited a potent activity in inhibiting platelet aggregation stimulated by collagen; however, it did not inhibit platelet aggregation stimulated by thrombin, arachidonic acid, or U46619. Treatment with ellagic acid (50 and 80 M) significantly inhibited platelet activation stimulated by collagen; this alteration was accompanied by the inhibition of relative [ Ca 2+ ] i mobilization, and the phosphorylation of phospholipase C (PLC)γ2, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt, as well as hydroxyl radical (OH) formation. In addition, ellagic acid also inhibited p38 MAPK and Akt phosphorylation stimulated by hydrogen peroxide. By contrast, ellagic acid did not significantly affect PKC activation and platelet aggregation stimulated by PDBu. This study is the first to show that, in addition to being considered a possible agent for preventing tumor growth, ellagic acid possesses potent antiplatelet properties. It appears to initially inhibit the PLC γ 2-PKC cascade and/or hydroxyl radical formation, followed by decreased phosphorylation of MAPKs and Akt, ultimately inhibiting platelet aggregation.

AB - Pomegranates are widely consumed either as fresh fruit or in beverage form as juice and wine. Ellagic acid possesses potent antioxidative properties; it is known to be an effective phytotherapeutic agent with antimutagenic and anticarcinogenic qualities. Ellagic acid (20 to 80 M) exhibited a potent activity in inhibiting platelet aggregation stimulated by collagen; however, it did not inhibit platelet aggregation stimulated by thrombin, arachidonic acid, or U46619. Treatment with ellagic acid (50 and 80 M) significantly inhibited platelet activation stimulated by collagen; this alteration was accompanied by the inhibition of relative [ Ca 2+ ] i mobilization, and the phosphorylation of phospholipase C (PLC)γ2, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt, as well as hydroxyl radical (OH) formation. In addition, ellagic acid also inhibited p38 MAPK and Akt phosphorylation stimulated by hydrogen peroxide. By contrast, ellagic acid did not significantly affect PKC activation and platelet aggregation stimulated by PDBu. This study is the first to show that, in addition to being considered a possible agent for preventing tumor growth, ellagic acid possesses potent antiplatelet properties. It appears to initially inhibit the PLC γ 2-PKC cascade and/or hydroxyl radical formation, followed by decreased phosphorylation of MAPKs and Akt, ultimately inhibiting platelet aggregation.

UR - http://www.scopus.com/inward/record.url?scp=84874895403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874895403&partnerID=8YFLogxK

U2 - 10.1155/2013/595128

DO - 10.1155/2013/595128

M3 - Article

C2 - 23533502

AN - SCOPUS:84874895403

VL - 2013

JO - Evidence-based Complementary and Alternative Medicine

JF - Evidence-based Complementary and Alternative Medicine

SN - 1741-427X

M1 - 595128

ER -